NAGE
Niagen Bioscience, Inc.
NASDAQ: NAGE · HEALTHCARE · BIOTECHNOLOGY
$4.76
-1.65% today
Updated 2026-04-29
Market cap
$381.18M
P/E ratio
23.80
P/S ratio
2.95x
EPS (TTM)
$0.20
Dividend yield
—
52W range
$4 – $15
Volume
1.2M
Niagen Bioscience, Inc. (NAGE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
13.40%
Operating margin
6.22%
ROE
28.30%
ROA
10.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2007 | — | $-38382.00 | — | — | — |
| 2008 | $4.51M | $-2.10M | 27.33% | -45.80% | -46.70% |
| 2009 | $5.78M | $-907568.00 | 35.33% | -15.45% | -15.71% |
| 2010 | $7.57M | $-2.05M | 38.92% | -26.66% | -27.12% |
| 2011 | $8.11M | $-7.89M | 30.47% | -96.94% | -97.32% |
| 2012 | $11.61M | $-11.66M | 19.60% | -100.22% | -100.45% |
| 2013 | $10.16M | $-4.42M | 30.84% | -43.17% | -43.50% |
| 2014 | $15.31M | $-5.39M | 34.78% | -34.16% | -35.19% |
| 2015 | $17.88M | $-2.77M | 42.13% | -11.55% | -15.49% |
| 2016 | $21.66M | $-2.93M | 47.96% | -13.41% | -13.52% |
| 2017 | $21.20M | $-11.38M | 49.42% | -77.25% | -53.67% |
| 2018 | $31.56M | $-33.32M | 50.88% | -105.12% | -105.57% |
| 2019 | $46.29M | $-32.15M | 55.67% | -67.62% | -69.45% |
| 2020 | $59.26M | $-19.93M | 59.53% | -33.50% | -33.62% |
| 2021 | $67.45M | $-27.13M | 61.51% | -40.14% | -40.22% |
| 2022 | $72.05M | $-16.54M | 59.40% | -25.85% | -22.96% |
| 2023 | $83.57M | $-4.94M | 60.76% | -6.70% | -5.91% |
| 2024 | $99.60M | $8.55M | 61.84% | 7.76% | 8.58% |
| 2025 | $129.42M | $17.38M | 64.28% | 11.05% | 13.43% |